Format

Send to

Choose Destination
See comment in PubMed Commons below
Vet J. 2006 May;171(3):556-8.

The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.

Author information

1
Sacramento Animal Medical Group, Cancer Treatment Center, 4990 Manzanita Avenue, Carmichael, CA 95608, USA. oncologyvet@yahoo.com

Abstract

Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did not bind or deplete canine B cells and it is unlikely that it will be added to the armamentarium of treatment options for canine lymphoma.

PMID:
16624725
DOI:
10.1016/j.tvjl.2005.03.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center